Jonathan Siegal Sells 4,500 Shares of Vericel (NASDAQ:VCEL) Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 4,500 shares of the firm’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $48.90, for a total value of $220,050.00. Following the sale, the insider owned 1,078 shares in the company, valued at $52,714.20. This trade represents a 80.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jonathan Siegal also recently made the following trade(s):

• On Friday, June 26th, Jonathan Siegal sold 2,732 shares of Vericel stock. The shares were sold at an average price of $44.90, for a total value of $122,666.80.

Vericel Trading Down 3.5%

NASDAQ VCEL opened at $45.96 on Friday. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of 97.79 and a beta of 1.07. The stock has a 50-day moving average of $41.95 and a 200 day moving average of $37.39. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $49.32.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. Vericel had a return on equity of 6.91% and a net margin of 7.91%.The company had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.70 million. During the same period last year, the company earned ($0.01) earnings per share. Vericel’s quarterly revenue was up 22.5% compared to the same quarter last year. Equities analysts predict that Vericel Corporation will post 0.49 EPS for the current fiscal year.

Key Headlines Impacting Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported second-quarter revenue of $77.5 million, up 22% year over year and above the $72.7 million consensus estimate. Earnings were $0.04 per share, beating expectations for a $0.04 loss, while net income reached $2.2 million and free cash flow was $14.3 million. Vericel Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $330 million-$340 million, a range that brackets or modestly exceeds the $331.9 million analyst consensus. MACI revenue growth of 23% was a key contributor to the quarterly performance. Vericel Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: The board authorized a $200 million share-repurchase program, which could support earnings per share and signal confidence in Vericel’s cash-generation outlook. Share Repurchase Program Announcement
• Positive Sentiment: Truist reaffirmed its Buy rating and increased its price target to $58 from $54. HC Wainwright also reaffirmed a Buy rating, reinforcing the favorable analyst view. Truist Financial Analyst Rating HC Wainwright Analyst Rating
• Neutral Sentiment: The earnings-call transcript and presentation provide additional operating details but do not indicate a separate material catalyst beyond the reported results and guidance. Q2 2026 Earnings Presentation
• Neutral Sentiment: Analyst sentiment is not unanimous, and Vericel trades at a high earnings multiple, leaving the shares sensitive to any slowdown in growth or weaker-than-expected future results. Conflicting Analyst Sentiment

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Truist Financial reissued a “buy” rating and issued a $58.00 price target (up from $54.00) on shares of Vericel in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Vericel in a report on Tuesday, July 28th. TD Cowen upped their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a research report on Thursday. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $58.40.

Hedge Funds Weigh In On Vericel

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Vericel by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 3,584,006 shares of the biotechnology company’s stock worth $129,060,000 after acquiring an additional 68,368 shares during the last quarter. State Street Corp raised its stake in Vericel by 12.7% in the 4th quarter. State Street Corp now owns 3,163,922 shares of the biotechnology company’s stock valued at $113,933,000 after purchasing an additional 356,680 shares during the last quarter. Conestoga Capital Advisors LLC raised its stake in Vericel by 9.3% in the 1st quarter. Conestoga Capital Advisors LLC now owns 2,463,312 shares of the biotechnology company’s stock valued at $79,245,000 after purchasing an additional 208,750 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Vericel by 0.5% in the 4th quarter. William Blair Investment Management LLC now owns 2,222,107 shares of the biotechnology company’s stock valued at $80,018,000 after purchasing an additional 11,178 shares in the last quarter. Finally, GW&K Investment Management LLC lifted its holdings in Vericel by 22.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,580,967 shares of the biotechnology company’s stock valued at $56,931,000 after purchasing an additional 290,795 shares in the last quarter.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.